Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review.

Jancel T, Shaw PA, Hallahan CW, Kim T, Freeman AF, Holland SM, Penzak SR.

J Clin Pharm Ther. 2017 Feb;42(1):75-79. doi: 10.1111/jcpt.12483. Epub 2016 Dec 16.

2.

CD8(+) T-cell Cytotoxic Capacity Associated with Human Immunodeficiency Virus-1 Control Can Be Mediated through Various Epitopes and Human Leukocyte Antigen Types.

Migueles SA, Mendoza D, Zimmerman MG, Martins KM, Toulmin SA, Kelly EP, Peterson BA, Johnson SA, Galson E, Poropatich KO, Patamawenu A, Imamichi H, Ober A, Rehm CA, Jones S, Hallahan CW, Follmann DA, Connors M.

EBioMedicine. 2014 Dec 22;2(1):46-58. doi: 10.1016/j.ebiom.2014.12.009. eCollection 2015 Jan.

3.

Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir.

Chun TW, Murray D, Justement JS, Blazkova J, Hallahan CW, Fankuchen O, Gittens K, Benko E, Kovacs C, Moir S, Fauci AS.

Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13151-6. doi: 10.1073/pnas.1414148111. Epub 2014 Aug 25.

4.

Effect of antiretroviral therapy on HIV reservoirs in elite controllers.

Chun TW, Shawn Justement J, Murray D, Kim CJ, Blazkova J, Hallahan CW, Benko E, Costiniuk CT, Kandel G, Ostrowski M, Kaul R, Moir S, Casazza JP, Koup RA, Kovacs C, Fauci AS.

J Infect Dis. 2013 Nov 1;208(9):1443-7. doi: 10.1093/infdis/jit306. Epub 2013 Jul 11.

5.

Cytotoxic capacity of SIV-specific CD8(+) T cells against primary autologous targets correlates with immune control in SIV-infected rhesus macaques.

Mendoza D, Migueles SA, Rood JE, Peterson B, Johnson S, Doria-Rose N, Schneider D, Rakasz E, Trivett MT, Trubey CM, Coalter V, Hallahan CW, Watkins D, Franchini G, Lifson JD, Connors M.

PLoS Pathog. 2013 Feb;9(2):e1003195. doi: 10.1371/journal.ppat.1003195. Epub 2013 Feb 28.

6.

Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy.

Blazkova J, Chun TW, Belay BW, Murray D, Justement JS, Funk EK, Nelson A, Hallahan CW, Moir S, Wender PA, Fauci AS.

J Infect Dis. 2012 Sep 1;206(5):765-9. doi: 10.1093/infdis/jis412. Epub 2012 Jun 25.

7.

Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding.

Smalls-Mantey A, Doria-Rose N, Klein R, Patamawenu A, Migueles SA, Ko SY, Hallahan CW, Wong H, Liu B, You L, Scheid J, Kappes JC, Ochsenbauer C, Nabel GJ, Mascola JR, Connors M.

J Virol. 2012 Aug;86(16):8672-80. doi: 10.1128/JVI.00287-12. Epub 2012 Jun 6.

8.

Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort.

Carroll MW, Lee M, Cai Y, Hallahan CW, Shaw PA, Min JH, Goldfeder LC, Alekseyev V, Grinkrug S, Kang HS, Hwang S, Park HM, Kang E, Lee SY, Jin B, Park HE, Min S, Park SK, Jeon DS, Via LE, Barry CE 3rd.

Int J Tuberc Lung Dis. 2012 Jul;16(7):961-6. doi: 10.5588/ijtld.11.0574. Epub 2012 May 8.

9.

Comprehensive analysis of unique cases with extraordinary control over HIV replication.

Mendoza D, Johnson SA, Peterson BA, Natarajan V, Salgado M, Dewar RL, Burbelo PD, Doria-Rose NA, Graf EH, Greenwald JH, Hodge JN, Thompson WL, Cogliano NA, Chairez CL, Rehm CA, Jones S, Hallahan CW, Kovacs JA, Sereti I, Sued O, Peel SA, O'Connell RJ, O'Doherty U, Chun TW, Connors M, Migueles SA.

Blood. 2012 May 17;119(20):4645-55. doi: 10.1182/blood-2011-10-381996. Epub 2012 Apr 5.

10.

Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy.

Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, Fauci AS.

J Infect Dis. 2011 Jul 1;204(1):135-8. doi: 10.1093/infdis/jir208.

11.

Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles.

Migueles SA, Rood JE, Berkley AM, Guo T, Mendoza D, Patamawenu A, Hallahan CW, Cogliano NA, Frahm N, Duerr A, McElrath MJ, Connors M.

PLoS Pathog. 2011 Feb;7(2):e1002002. doi: 10.1371/journal.ppat.1002002. Epub 2011 Feb 24.

12.

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.

Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, Collier AC, Sheth PM, Kaul R, Ostrowski M, Moir S, Kovacs C, Fauci AS.

AIDS. 2010 Nov 27;24(18):2803-8. doi: 10.1097/QAD.0b013e328340a239.

13.

A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda.

Reynolds SJ, Kityo C, Hallahan CW, Kabuye G, Atwiine D, Mbamanya F, Ssali F, Dewar R, Daucher M, Davey RT Jr, Mugyenyi P, Fauci AS, Quinn TC, Dybul MR.

PLoS One. 2010 Apr 22;5(4):e10307. doi: 10.1371/journal.pone.0010307.

14.

Defective plasmacytoid dendritic cell-NK cell cross-talk in HIV infection.

Reitano KN, Kottilil S, Gille CM, Zhang X, Yan M, O'Shea MA, Roby G, Hallahan CW, Yang J, Lempicki RA, Arthos J, Fauci AS.

AIDS Res Hum Retroviruses. 2009 Oct;25(10):1029-37. doi: 10.1089/aid.2008.0311.

15.

Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy.

Migueles SA, Weeks KA, Nou E, Berkley AM, Rood JE, Osborne CM, Hallahan CW, Cogliano-Shutta NA, Metcalf JA, McLaughlin M, Kwan R, Mican JM, Davey RT Jr, Connors M.

J Virol. 2009 Nov;83(22):11876-89. doi: 10.1128/JVI.01153-09. Epub 2009 Sep 2.

16.

Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy.

Nies-Kraske E, Schacker TW, Condoluci D, Orenstein J, Brenchley J, Fox C, Daucher M, Dewar R, Urban E, Hill B, Guenaga J, Hoover S, Maldarelli F, Hallahan CW, Horn J, Kottilil S, Chun TW, Folino M, Palmer S, Wiegand A, O'Shea MA, Metcalf JA, Douek DC, Coffin J, Haase A, Fauci AS, Dybul M.

J Infect Dis. 2009 Jun 1;199(11):1648-56. doi: 10.1086/598980.

17.

Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness.

Jagannathan P, Osborne CM, Royce C, Manion MM, Tilton JC, Li L, Fischer S, Hallahan CW, Metcalf JA, McLaughlin M, Pipeling M, McDyer JF, Manley TJ, Meier JL, Altman JD, Hertel L, Davey RT Jr, Connors M, Migueles SA.

J Virol. 2009 Mar;83(6):2728-42. doi: 10.1128/JVI.02128-08. Epub 2009 Jan 7.

18.

Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control.

Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, Weeks KA, Rood JE, Berkley AM, Sacha JB, Cogliano-Shutta NA, Lloyd M, Roby G, Kwan R, McLaughlin M, Stallings S, Rehm C, O'Shea MA, Mican J, Packard BZ, Komoriya A, Palmer S, Wiegand AP, Maldarelli F, Coffin JM, Mellors JW, Hallahan CW, Follman DA, Connors M.

Immunity. 2008 Dec 19;29(6):1009-21. doi: 10.1016/j.immuni.2008.10.010. Epub 2008 Dec 8.

19.

Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.

Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, Hallahan CW, Migueles SA, Wrammert J, Ahmed R, Nason M, Wyatt RT, Mascola JR, Connors M.

J Virol. 2009 Jan;83(1):188-99. doi: 10.1128/JVI.01583-08. Epub 2008 Oct 15.

20.

Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy.

Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, Kottilil S, Moir S, Mican JM, Mullins JI, Ward DJ, Kovacs JA, Mannon PJ, Fauci AS.

J Infect Dis. 2008 Mar 1;197(5):714-20. doi: 10.1086/527324.

PMID:
18260759
21.

Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro.

Tilton JC, Manion MM, Luskin MR, Johnson AJ, Patamawenu AA, Hallahan CW, Cogliano-Shutta NA, Mican JM, Davey RT Jr, Kottilil S, Lifson JD, Metcalf JA, Lempicki RA, Connors M.

J Virol. 2008 Apr;82(8):3997-4006. doi: 10.1128/JVI.01545-07. Epub 2008 Feb 6.

22.

Innate immunity in HIV infection: enhanced susceptibility to CD95-mediated natural killer cell death and turnover induced by HIV viremia.

Kottilil S, Jackson JO, Reitano KN, O'Shea MA, Roby G, Lloyd M, Yang J, Hallahan CW, Rehm CA, Arthos J, Lempicki R, Fauci AS.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):151-9.

PMID:
17558334
23.

Impact of HIV on cell survival and antiviral activity of plasmacytoid dendritic cells.

Meyers JH, Justement JS, Hallahan CW, Blair ET, Sun YA, O'Shea MA, Roby G, Kottilil S, Moir S, Kovacs CM, Chun TW, Fauci AS.

PLoS One. 2007 May 23;2(5):e458.

24.

Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.

Chun TW, Justement JS, Moir S, Hallahan CW, Maenza J, Mullins JI, Collier AC, Corey L, Fauci AS.

J Infect Dis. 2007 Jun 15;195(12):1762-4. Epub 2007 May 2.

PMID:
17492591
25.

Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load.

Tilton JC, Luskin MR, Johnson AJ, Manion M, Hallahan CW, Metcalf JA, McLaughlin M, Davey RT Jr, Connors M.

J Virol. 2007 Mar;81(6):2713-25. Epub 2006 Dec 20.

26.

Diminished production of monocyte proinflammatory cytokines during human immunodeficiency virus viremia is mediated by type I interferons.

Tilton JC, Johnson AJ, Luskin MR, Manion MM, Yang J, Adelsberger JW, Lempicki RA, Hallahan CW, McLaughlin M, Mican JM, Metcalf JA, Iyasere C, Connors M.

J Virol. 2006 Dec;80(23):11486-97. Epub 2006 Sep 27.

27.

Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients.

Keh CE, Shen JM, Hahn B, Hallahan CW, Rehm CA, Thaker V, Wynne SM, Davey RT, Lane HC, Sereti I.

AIDS. 2006 Feb 14;20(3):361-9.

PMID:
16439869
28.

Innate immune dysfunction in HIV infection: effect of HIV envelope-NK cell interactions.

Kottilil S, Shin K, Jackson JO, Reitano KN, O'Shea MA, Yang J, Hallahan CW, Lempicki R, Arthos J, Fauci AS.

J Immunol. 2006 Jan 15;176(2):1107-14.

29.

HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir.

Chun TW, Nickle DC, Justement JS, Large D, Semerjian A, Curlin ME, O'Shea MA, Hallahan CW, Daucher M, Ward DJ, Moir S, Mullins JI, Kovacs C, Fauci AS.

J Clin Invest. 2005 Nov;115(11):3250-5.

30.

A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection.

Dybul M, Nies-Kraske E, Dewar R, Maldarelli F, Hallahan CW, Daucher M, Piscitelli SC, Ehler L, Weigand A, Palmer S, Metcalf JA, Davey RT, Rock Kress DM, Powers A, Beck I, Frenkel L, Baseler M, Coffin J, Fauci AS.

J Infect Dis. 2004 Jun 1;189(11):1974-82. Epub 2004 May 10.

PMID:
15143462
31.

IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation.

Sereti I, Anthony KB, Martinez-Wilson H, Lempicki R, Adelsberger J, Metcalf JA, Hallahan CW, Follmann D, Davey RT, Kovacs JA, Lane HC.

Blood. 2004 Aug 1;104(3):775-80. Epub 2004 Apr 13.

PMID:
15090457
32.

Expression of chemokine and inhibitory receptors on natural killer cells: effect of immune activation and HIV viremia.

Kottilil S, Shin K, Planta M, McLaughlin M, Hallahan CW, Ghany M, Chun TW, Sneller MC, Fauci AS.

J Infect Dis. 2004 Apr 1;189(7):1193-8. Epub 2004 Mar 16.

PMID:
15031787
33.

Relationship between the frequency of HIV-specific CD8+ T cells and the level of CD38+CD8+ T cells in untreated HIV-infected individuals.

Chun TW, Justement JS, Sanford C, Hallahan CW, Planta MA, Loutfy M, Kottilil S, Moir S, Kovacs C, Fauci AS.

Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2464-9.

34.

Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2.

Iyasere C, Tilton JC, Johnson AJ, Younes S, Yassine-Diab B, Sekaly RP, Kwok WW, Migueles SA, Laborico AC, Shupert WL, Hallahan CW, Davey RT Jr, Dybul M, Vogel S, Metcalf J, Connors M.

J Virol. 2003 Oct;77(20):10900-9.

35.

Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters.

Dybul M, Nies-Kraske E, Daucher M, Hertogs K, Hallahan CW, Csako G, Yoder C, Ehler L, Sklar PA, Belson M, Hidalgo B, Metcalf JA, Davey RT, Rock Kress DM, Powers A, Fauci AS.

J Infect Dis. 2003 Aug 1;188(3):388-96. Epub 2003 Jul 10.

PMID:
12870120
36.

Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function.

Malaspina A, Moir S, Kottilil S, Hallahan CW, Ehler LA, Liu S, Planta MA, Chun TW, Fauci AS.

J Immunol. 2003 Jun 15;170(12):5965-72.

37.

The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences.

Migueles SA, Laborico AC, Imamichi H, Shupert WL, Royce C, McLaughlin M, Ehler L, Metcalf J, Liu S, Hallahan CW, Connors M.

J Virol. 2003 Jun;77(12):6889-98.

38.

Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals.

Moir S, Ogwaro KM, Malaspina A, Vasquez J, Donoghue ET, Hallahan CW, Liu S, Ehler LA, Planta MA, Kottilil S, Chun TW, Fauci AS.

Proc Natl Acad Sci U S A. 2003 May 13;100(10):6057-62. Epub 2003 May 1.

39.

Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function.

Kottilil S, Chun TW, Moir S, Liu S, McLaughlin M, Hallahan CW, Maldarelli F, Corey L, Fauci AS.

J Infect Dis. 2003 Apr 1;187(7):1038-45. Epub 2003 Mar 13.

PMID:
12660917
40.

Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy.

Dybul M, Daucher M, Jensen MA, Hallahan CW, Chun TW, Belson M, Hidalgo B, Nickle DC, Yoder C, Metcalf JA, Davey RT, Ehler L, Kress-Rock D, Nies-Kraske E, Liu S, Mullins JI, Fauci AS.

J Virol. 2003 Mar;77(5):3229-37.

41.

Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals.

Chun TW, Justement JS, Lempicki RA, Yang J, Dennis G Jr, Hallahan CW, Sanford C, Pandya P, Liu S, McLaughlin M, Ehler LA, Moir S, Fauci AS.

Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1908-13. Epub 2003 Jan 27.

42.

HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors.

Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, Van Baarle D, Kostense S, Miedema F, McLaughlin M, Ehler L, Metcalf J, Liu S, Connors M.

Nat Immunol. 2002 Nov;3(11):1061-8. Epub 2002 Oct 7.

PMID:
12368910
43.

Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells.

Sereti I, Martinez-Wilson H, Metcalf JA, Baseler MW, Hallahan CW, Hahn B, Hengel RL, Davey RT, Kovacs JA, Lane HC.

Blood. 2002 Sep 15;100(6):2159-67.

PMID:
12200381
44.

Evaluation of initial CD4+ T cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settings.

Dybul M, Bolan R, Condoluci D, Cox-Iyamu R, Redfield R, Hallahan CW, Folino M, Sathasivam K, Weisberg M, Andrews M, Hidalgo B, Vasquez J, Fauci AS.

J Infect Dis. 2002 Jun 15;185(12):1818-21. Epub 2002 May 31.

PMID:
12085332
45.
46.

Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection.

Dybul M, Hidalgo B, Chun TW, Belson M, Migueles SA, Justement JS, Herpin B, Perry C, Hallahan CW, Davey RT, Metcalf JA, Connors M, Fauci AS.

J Infect Dis. 2002 Jan 1;185(1):61-8. Epub 2001 Dec 14.

PMID:
11756982
47.

Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters.

Dybul M, Chun TW, Yoder C, Hidalgo B, Belson M, Hertogs K, Larder B, Dewar RL, Fox CH, Hallahan CW, Justement JS, Migueles SA, Metcalf JA, Davey RT, Daucher M, Pandya P, Baseler M, Ward DJ, Fauci AS.

Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15161-6. Epub 2001 Dec 4.

48.

High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation.

McNeil AC, Shupert WL, Iyasere CA, Hallahan CW, Mican JA, Davey RT Jr, Connors M.

Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13878-83.

49.

CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients.

Sereti I, Herpin B, Metcalf JA, Stevens R, Baseler MW, Hallahan CW, Kovacs JA, Davey RT, Lane HC.

AIDS. 2001 Sep 28;15(14):1765-75.

PMID:
11579237
50.

HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals.

Moir S, Malaspina A, Ogwaro KM, Donoghue ET, Hallahan CW, Ehler LA, Liu S, Adelsberger J, Lapointe R, Hwu P, Baseler M, Orenstein JM, Chun TW, Mican JA, Fauci AS.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10362-7. Epub 2001 Aug 14.

Supplemental Content

Loading ...
Support Center